Levi & Korsinsky announces it has commenced an investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

On March 7, 2016, Celldex stock fell more than 50% on intraday trading following the Company's disclosure that it will discontinue its late-stage study of RINTEGA. In a Company press release, Celldex noted that an independent Data Safety and Monitoring Board found that the trial will likely "not reach statistical significant for overall survival in patients with minimal residual disease, the primary end-point of the study." To obtain additional information about this investigation, go to:

http://zlk.9nl.com/celldex-therapeutics-cldx

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160307006444/en/

Copyright Business Wire 2010